Drug Trial Radar · NCT07750158
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Dec 18, 2026
Primary completion
Apr 5, 2030
Study completion Apr 5, 2030
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Conditions
- Colorectal Cancer
Interventions
ZanzalintinibDrug
Oral tablets administered once daily.
Pembrolizumab (+) Berahyaluronidase alfaBiological
Pembrolizumab + berahyaluronidase alfa fixed-dose combination administered via subcutaneous (SC) injection once every 3 weeks (Q3W).
PlaceboDrug
Placebo to match zanzalintinib oral tablets administered once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the InvestigatorTime frame: Up to 24 months
- DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the InvestigatorTime frame: Up to 24 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida · Recruiting
Orlando Health Cancer Institute
Lake Mary, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Low Country Cancer Care
Savannah, Georgia · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs
Council Bluffs, Iowa · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island
Grand Island, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional
Grand Island, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist
Omaha, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan
Omaha, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy
Omaha, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Papillion
Papillion, Nebraska · Recruiting
Astera Cancer Care
Bridgewater, New Jersey · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Astera Cancer Care
Edison, New Jersey · Recruiting
Astera Cancer Care
Monroe, New Jersey · Recruiting
Astera Cancer Care
Somerset, New Jersey · Recruiting
Astera Cancer Care
Toms River, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.